How to assess the external validity of therapeutic trials: a conceptual approach

Dekkers, O. M.; von Elm, E.; Algra, A.; Romijn, J. A.; Vandenbroucke, J. P.
February 2010
International Journal of Epidemiology;Feb2010, Vol. 39 Issue 1, p89
Academic Journal
Background External validity of study results is an important issue from a clinical point of view. From a methodological point of view, however, the concept of external validity is more complex than it seems to be at first glance.


Related Articles

  • Recruiters Always Strive to Improve. Ganter, Jane // Applied Clinical Trials;Mar2010, Vol. 19 Issue 3, p2 

    An introduction is presented in which the editor lays out the issue's theme of effective subject recruitment in clinical trials.

  • Post-randomisation exclusions: the intention to treat principle and excluding patients from analysis. Ferguson, Dean; Aaron, Shawn D.; Guyatt, Gordon; Hebert, Paul // BMJ: British Medical Journal (International Edition);9/21/2002, Vol. 325 Issue 7365, p652 

    Analyzes when it is legitimate to exclude randomized patients from the analysis of data in clinical trials. Exclusion when ineligible patients are mistakenly randomized into a trial; Exclusion of patients who were prematurely randomized and did not receive an intervention; Inclusion of data...

  • CTTI recommends informed consent process reform. Korieth, Karyn // CenterWatch Weekly;11/30/2015, Vol. 19 Issue 47, p1 

    The article reports that the private-public partnership Clinical Trials Transformation Initiative (CTTI) has recommended a new model for the informed consent process reform to improve the ability of patients deciding to participate in clinical research.

  • BED REST AND NORMAL DAILY ACTIVITY WERE EQUIVALENT FOR ACUTE LOW-BACK PAIN. Rozenberg, S; Delval, C; Rezvani, Y // Journal of Bone & Joint Surgery, American Volume;May2003, Vol. 85-A Issue 5, p975 

    There article examines whether in patients with acute low-back pain, is 4 days of bed rest more effective than continued normal daily activity, taking into account a patient's type of work. Patients were stratified by their type of work and were allocated to treatment with 4 days of bed rest or...

  • TO WHOM DO THE RESEARCH FINDINGS APPLY? Furberg, Curt D. // Heart;Jun2002, Vol. 87 Issue 6, p570 

    This article presents the authors views on research works related to general cardiology. The clinical trials conducted to determine efficacy and safety of new interventions are typically designed to be feasible and time and cost efficient. As a consequence, trial populations are typically highly...

  • The lesser known effects of statins. Thomsen, Reimar W. // BMJ: British Medical Journal (International Edition);11/11/2006, Vol. 333 Issue 7576, p980 

    The author focuses on a study in this issue called "Statins and outcomes in patients admitted to hospital with community acquired pneumonia: population based prospective cohort study," by Sumit R. Majumdar and colleagues. The author notes that their findings on infectious outcomes may differ...

  • Adaptive designs for binary treatment responses in phase III clinical trials: controversies and progress. Biswas, A. // Statistical Methods in Medical Research;Oct2001, Vol. 10 Issue 5, p353 

    In phase III clinical trials the problem is to compare two treatments or therapies for their effects. The randomized 50:50 allocation to the two competing treatments is popular in most of the cases. In contrast there is a class of adaptive designs available in literature for this purpose. The...

  • Why Sackett's analysis of randomized controlled trials fails, but needn't. Shapiro, Stanley H.; Glass, Kathleen Cranley // CMAJ: Canadian Medical Association Journal;10/03/2000, Vol. 163 Issue 7, p834 

    Discusses the role of randomized clinical trials and its importance to competing treatments. View of physician Dave Sackett that a physician must be substantially uncertain about the merits of a treatment to ethically recommend enrollment for a patient; Suggestion that the certainty of an...

  • Analysis of Unbiased Histopathology Data from Rodent Toxicity Studies (or, Are These Groups Different Enough to Ascribe It to Treatment?). HOLLAND, TOM; HOLLAND, CHRISTOPHER // Toxicologic Pathology;Jun2011, Vol. 39 Issue 4, p569 

    It is a common problem to distinguish a minor treatment change from background variation, especially when establishing no observed effect levels. Toxicological histopathologists use a wide range of methods at the microscope for comparing groups to help them form their opinions. Although the data...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics